InvestorsHub Logo
Followers 10
Posts 282
Boards Moderated 0
Alias Born 10/13/2013

Re: joboggi post# 87739

Wednesday, 10/23/2013 2:45:13 AM

Wednesday, October 23, 2013 2:45:13 AM

Post# of 130513

there is no chance that any compound would be able to skip a phase 1 study.



I agree with this and that's why I thought Risk's scenario was unlikely (to say the least). For me the funding that Mart Saarma received for studying MANF/DB is what is most interesting. I think we're all aware that he's not studying MANF/PD.


My question for you regarding the Biomarker Discovery Center's work on a blood test for AD has to do with it being ahead of Lympro. By 'ahead' do you mean that it's on target for commercialization ahead of 2H 2014? If not, in what way is it 'ahead'?